This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 | M05.2 |
| Synonyms / related terms | Rheumatoid arthritis–associated systemic vasculitis, RA vasculitis |
| Special Copayment Reduction | V223 — severe intractable disease (10% copayment, 5 years) |
| Main age of onset | Mainly in RA patients with long disease duration (10 years or more after onset), and in seropositive men |
Contents
| s1 | History |
| s2 | Causes |
| s3 | Genetics |
| s4 | General epidemiology |
| s5 | Pathophysiology |
| s6 | Symptoms |
| s7 | Signs |
| s8 | Screening |
| s9 | Diagnosis |
| s10 | Treatment |
| s11 | Prognosis |
| s12 | Prevention |
| s13 | References |
Rheumatoid vasculitis (RV) has been recognized as a severe systemic complication of RA since Bannatyne first described perivascular inflammation in rheumatoid arthritis patients in 1898. In 1954, Sokoloff et al. reported that vasculitis was frequently found at autopsy of RA patients who died, and from the 1960s a clinicopathologic classification encompassing involvement of the skin, nervous system, heart, and organ vessels was established. In the 1970s–80s, deposition of immunoglobulin and complement complexes in the vessel wall was confirmed by immunofluorescence, and an immune complex–mediated vascular injury mechanism was proposed. As high-titer rheumatoid factor (RF), anti-CCP antibodies, and antineutrophil cytoplasmic antibodies (ANCA) were found to be associated with the development of RV, the clinical role of serologic markers came to the fore. Since the 1990s, after the introduction of biologic agents including TNF inhibitors, the incidence of severe RV has decreased significantly, suggesting that thorough control of RA inflammation is effective in preventing vasculitis. Recently, monocyte/macrophage polarization and NET (neutrophil extracellular trap) formation are being studied as mechanisms contributing to the pathogenesis of RV.
The development of RV is most strongly associated with high-titer seropositive RA (high titers of RF IgM, IgG, and IgA and anti-CCP IgG). Long disease duration, inadequate RA control, smoking, and male sex are risk factors for RV. Deposition of immune complexes (RF + IgG complexes) within the vessel wall activates the complement pathway and attracts neutrophils and monocytes, damaging the vascular endothelium. Small-vessel vasculitis is reported more frequently in RA patients who are ANCA-positive (perinuclear, PR3- or MPO-specific), suggesting that RA-associated vasculitis may overlap in phenotype with ANCA-associated vasculitis. Drugs that induce cutaneous vasculitis (sulfasalazine, D-penicillamine, hydralazine) can rarely cause a similar clinical picture and need to be differentiated. Whether autoantibodies against citrullinated proteins of vascular endothelial cells directly contribute to endothelial injury is also under study.
The genetic risk of RV is strongly associated with the HLA-DRB1 shared epitope alleles of RA itself (especially *04:01, *04:04), and increases the risk of developing RV through high-titer RF and anti-CCP positivity. HLA-C*03:04 has been reported to be independently associated with RV in some cohorts. The PTPN22 R620W polymorphism (rs2476601) has been suggested to be associated with the vascular involvement phenotype in RF-positive RA. In ANCA-positive RV patients, genetic risk factors for ANCA-associated vasculitis (SERPINA1, PRTN3, HLA-DP1) may act additively on top of the RA background. The low-expression IL-10 promoter polymorphism may contribute to persistent immune complex–mediated vascular injury through deficiency of an anti-inflammatory cytokine. Clustering of the vasculitis phenotype in familial RA has been reported, supporting the importance of genetic predisposition, but gene-specific studies are still limited by small sample sizes.
In the pre-biologic era, the incidence of clinically significant RV was reported at about 5–10% of RA patients, but in large cohort studies after the spread of TNF inhibitors it decreased to about 1–3%. Cutaneous vasculitis (leukocytoclastic vasculitis, palpable purpura, periungual infarcts) is the most common clinical manifestation, and peripheral nervous system involvement (mononeuritis multiplex) is the second most common. Visceral vasculitis (mesenteric, coronary, renal arteries) is rare but can be fatal. The risk of occurrence is high in men, long disease duration (mean disease duration about 10–15 years), high-titer seropositivity, presence of subcutaneous nodules, and smokers. RV occurring in the biologic era is predominantly cutaneous compared with before, and visceral and nervous system involvement has become rare. Independent reports on RV prevalence in Korean RA cohorts are rare, and the incidence is presumed to be lower than in the West.
The pathology of RV appears mainly as necrotizing vasculitis of small vessels (arterioles, capillaries, venules) and medium-sized vessels. Immune complexes formed when high-titer IgM RF binds to the IgG Fc region deposit in the vessel wall and activate complement (C3, C4, C5b-9 membrane attack complex). Complement activation causes vascular endothelial cell injury, neutrophil chemotaxis, and neutrophil degranulation (release of MPO and elastase). CD4+ T cells, especially Th1 cells, form perivascular inflammatory infiltrates and secrete IFN-γ to activate macrophages. Recently, evidence is increasing that neutrophil extracellular trap (NET) formation contributes to vascular endothelial injury, thrombus formation, and vasculitis pathology. Overexpression of ICAM-1, VCAM-1, and E-selectin on vascular endothelial cells promotes leukocyte adhesion, leading to endothelial cell death and vessel wall necrosis. Excess secretion of TNF-α, IL-1β, and IL-6 is the key mediator sustaining systemic vascular inflammation.
The clinical features of RV vary with the size of the vessels and the organs involved. Skin symptoms are the most common, with periungual infarcts, digital tip infarcts, palpable purpura, livedo reticularis, and skin ulcers. Peripheral nervous system involvement presents as mononeuritis multiplex, characterized by sudden digital nerve or peroneal nerve palsy. Sensory abnormalities, burning sensation, and neuropathic pain accompany. Medium-vessel vasculitis is accompanied by systemic symptoms such as fever, weight loss, and fatigue, with markedly elevated ESR and CRP. Mesenteric vasculitis can present with abdominal pain, bloody stool, and intestinal ischemia and requires immediate treatment. Coronary artery involvement can present as angina or myocardial infarction, and rarely accompanies serous pericarditis. Renovascular hypertension and decreased renal function due to renal artery involvement are also reported.
On skin examination, finding reddish-brown infarct spots around the nails, digital ulcers, and purpura of the lower limbs is often the first clue to RV. When peripheral nerve involvement is present, decreased sensation, trigger points for pain, and muscle weakness are confirmed in the relevant nerve distribution. On skin biopsy, leukocytoclastic vasculitis is typical. Palpable purpura tends to be distributed symmetrically on both lower limbs rather than non-bilaterally. When visceral involvement is present, abdominal tenderness and decreased or increased bowel sounds may be observed. Ocular vasculitis (involvement of scleral and retinal vessels) can appear as scleral injection, decreased vision, and retinal ischemia. In most RV patients, the signs of underlying RA with joint involvement (joint swelling, deformity, morning stiffness) coexist. ESR, CRP, RF, anti-CCP, decreased complement C3/C4, and cryoglobulinemia accompany as laboratory findings.
In RA patients with suspected RV, serum RF IgM/IgG/IgA, anti-CCP antibody, complement (C3, C4, CH50), cryoglobulin, and ANCA (MPO/PR3) tests are performed. On complete blood count, leukocytosis, reactive thrombocytosis, and mild anemia (anemia of chronic inflammation) are commonly observed. Urinalysis (proteinuria, red blood cell casts) screens for glomerular involvement. Biopsy of skin lesions is essential for confirming the pattern of vascular involvement and direct immunofluorescence findings (IgG, IgM, C3 deposition). Nerve conduction study (NCS)/electromyography (EMG) assesses the extent of peripheral neuropathy and the nerves involved. Chest X-ray and echocardiography are performed to exclude the possibility of cardiac involvement. CT angiography of the abdomen is performed when mesenteric vascular involvement is suspected. Ophthalmologic slit-lamp examination assesses scleral vasculitis and retinal vascular abnormalities.
The diagnosis of RV is established when, in a patient with established RA, clinical symptoms consistent with vasculitis (skin infarcts, mononeuritis multiplex, visceral ischemia) occur and histologic confirmation is obtained. Skin biopsy is the histologic diagnostic criterion for small-vessel vasculitis (leukocytoclastic vasculitis), and confirming IgG/IgM/C3 deposition by direct immunofluorescence is standard. Nerve biopsy (sural nerve, etc.) is used to confirm vasculitic neuropathy in patients with mononeuritis multiplex. Visceral vascular involvement is diagnosed through angiography, CT angiography, and surgical/tissue biopsy. Because ANCA-positive small-vessel vasculitis (MPA, GPA) can occur independently in RA patients, differentiation from the Chapel Hill classification criteria is important in clinically ambiguous cases. The 2012 ACR/EULAR vasculitis classification criteria do not include RV as an independent classification category, so diagnosis relies on clinicopathologic judgment.
Mild cutaneous RV (periungual infarcts, small-area purpura) is managed by optimizing underlying RA treatment (intensifying DMARDs, low-dose steroids). Smoking cessation is essential, and drugs that worsen vasoconstriction (beta blockers, etc.) are avoided if possible. For moderate to severe RV (ulcers, mononeuritis multiplex, visceral involvement), high-dose systemic steroids (prednisolone 1 mg/kg/day) are given immediately, and cyclophosphamide (IV pulse or oral) is added if the response is insufficient. Rituximab is used as an alternative to cyclophosphamide or as a maintenance treatment option. Abatacept and tocilizumab have shown effects at the case report level. TNF inhibitors may be associated with the development or worsening of vasculitis in some cases, so caution is needed, and they are generally avoided during active RV. Surgical treatment is needed when visceral ischemia or gastrointestinal perforation occurs. Anticoagulation is considered only when thrombotic complications accompany, and routine use for vasculitis itself is not recommended.
Severe visceral vasculitis (mesenteric, coronary artery involvement) has a very poor prognosis, with a 5-year mortality of 30–40%. Mononeuritis multiplex can partially recover with early treatment, but permanent neurologic deficits remain when axonal damage is severe. Mild cutaneous vasculitis mostly improves with appropriate treatment but tends to recur. Since the biologic era, the incidence and mortality of RV have decreased significantly, but when it occurs it is still an independent predictor of RA mortality. Low complement, cryoglobulinemia, high-titer RF, and ANCA positivity are poor prognostic factors. Infectious complications, bladder toxicity, and secondary malignancy after cyclophosphamide treatment contribute to long-term morbidity. Regular follow-up (evaluation of skin, nervous system, and visceral organs) and thorough control of RA activity are key to preventing recurrence.
The key to RV prevention is to control RA inflammation to the remission level early according to a treat-to-target (T2T) strategy. There is epidemiologic evidence that thoroughly suppressing RA activity with biologic agents including TNF inhibitors significantly reduces the incidence of RV. Smoking cessation reduces RV risk by suppressing vascular endothelial damage and immune complex formation. More aggressive RA control is needed in patients with high-titer RF/anti-CCP seropositivity. Regular skin examination to detect skin findings (periungual infarcts, purpura) early can prevent progression to severe vasculitis. Minimize use of NSAIDs and ergotamine-class drugs, which worsen vasoconstriction, and educate patients to avoid cold exposure. Improved nutritional status and appropriate exercise help maintain vascular endothelial function.
1. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76(3):377-84.
2. Watts RA, et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43(2):414-9.
3. Voskuyl AE, et al. The mortality of rheumatoid vasculitis compared with systemic vasculitis: a systematic review. Rheumatology. 1998;37(6):636-41.
4. Turesson C, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722-7.
5. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of RA. Nat Rev Rheumatol. 2013;9(4):191-204.
6. Puéchal X, et al. Rheumatoid vasculitis. Joint Bone Spine. 2007;74(5):427-35.
7. Ntatsaki E, et al. ACR/EULAR consensus methodology for classification criteria of rheumatoid vasculitis. Rheumatology. 2014;53(2):315-22.
8. Makol A, et al. Rheumatoid vasculitis: an unrecognized cause of mononeuritis multiplex. J Rheumatol. 2011;38(7):1345-8.
9. Barra L, et al. Immune-mediated vasculitis in rheumatoid arthritis: a systematic review. Semin Arthritis Rheum. 2018;47(4):503-9.
10. Ndosi M, et al. Outcomes in patients with RA and rheumatoid vasculitis — a CORRONA registry analysis. Arthritis Care Res. 2020;72(11):1578-85.